Skip to main content

CORRECTION article

Front. Med.
Sec. Rheumatology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1489092

Corrigendum: "Efficacy and Safety of Janus Kinase Inhibitors in Non-Infectious Inflammatory Ocular Diseases: A Prospective Cohort Study from the International AIDA Network Registries"

Provisionally accepted
  • 1 University of Siena, Siena, Italy
  • 2 Bellvitge University Hospital, Barcelona, Balearic Islands, Spain
  • 3 Cairo University, Giza, Giza, Egypt
  • 4 Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain
  • 5 Rosario University, Bogotá, Bogota, Colombia
  • 6 Cruces University Hospital, Barakaldo, Spain
  • 7 Hospital Universitario Rey Juan Carlos, Madrid, Madrid, Spain

The final, formatted version of the article will be published soon.

    Keywords: Baricitinib, Scleritis, Tofacitinib, Upadacitinib, Uveitis

    Received: 31 Aug 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Vitale, Palacios-Olid, Caggiano, Ragab, Hernández-Rodríguez, Pelegrín Colás, Mejía-Salgado, Zarate-Pinzón, Gentileschi, Sota, Fonollosa, Carreño, Gaggiano, Amin, Balistreri, Narvaez, Tosi, Frediani, Cantarini, de-la-Torre and Fabiani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Luca Cantarini, University of Siena, Siena, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.